Mandate

Vinge advises Manor Investment S.A. on investment in Rabbalshede Kraft AB (publ)

June 20, 2013

Vinge is advising Manor Investment S.A. in connection with its investment in Rabbalshede Kraft AB (publ). The investment is made through inter alia acquisition of newly issued shares of class B in a private placement, acquisition of 347,500 shares of class A from certain of the current main shareholders, and through acquisition of newly issued shares of class B in a rights issue. Manor is a private industrial company within the renewable energy sector providing long-term development capital to entrepreneurs and industrial projects in Europe aiming for the better use of energy and natural resources. Rabbalshede develops and operates wind power farms in Sweden, with a current portfolio of 26 wind turbines proprietarily managed, 14 turbines under construction and about 350 turbines in the procurement, application or planning phase. Closing of the transactions is subject to certain conditions precedent. Manor is advised by Treïs (www.treispartners.com).

The Vinge team advising Manor includes partner Michael Wigge and associates Peter Sundgren and Louise Markgren (M&A), partner Thomas Sjöberg and associate Johan Cederblad (Real Estate & Environmental), and associate Albert Wållgren (Banking & Finance).

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024